Skyhawk news

Browse:

Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression

June 25, 2024
Skyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location
Read
2 min read
April 22, 2024
Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D
Read
1 min read
September 30, 2020
The Endpoints 11 : Here are some of the most promising startups in biotech. And Covid-19 isn’t going to stop them
Read
2 min read
May 12, 2020
Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Skyhawk will deploy its SkySTAR™ platform to develop drug candidates directed to multiple new targets for autoimmune and metabolic diseases
Read
2 min read
May 12, 2020
Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target
Read
2 min read